A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants

Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain (RBD) of the spike (S) protein. Variants of concern (VOC) carrying mutations in the RBD or other regions of S reduce the effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Haslwanter, Denise, Dieterle, M. Eugenia, Wec, Anna Z., O’Brien, Cecilia M., Sakharkar, Mrunal, Florez, Catalina, Tong, Karen, Rappazzo, C. Garrett, Lasso, Gorka, Vergnolle, Olivia, Wirchnianski, Ariel S., Bortz, Robert H., Laudermilch, Ethan, Fels, J. Maximilian, Mengotto, Amanda, Malonis, Ryan J., Georgiev, George I., Quiroz, Jose A., Wrapp, Daniel, Wang, Nianshuang, Dye, Kathryn E., Barnhill, Jason, Dye, John M., McLellan, Jason S., Daily, Johanna P., Lai, Jonathan R., Herbert, Andrew S., Walker, Laura M., Chandran, Kartik, Jangra, Rohit K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546647/
https://www.ncbi.nlm.nih.gov/pubmed/34607456
http://dx.doi.org/10.1128/mBio.02473-21

Ejemplares similares

Ejemplares similares